| Type of adverse event |
With IVIgG* treatment 30 patients |
With SCIgG† treatment32 patients |
| |
Episodes in numbers (patients affected) |
Episodes in numbers (patients affected) |
| Mild |
3 (1) |
32 (5) |
| Local Erithema |
0 |
10 (4) |
| Local Swelling |
0 |
8 (2) |
| Local Pain |
3 (1) |
10 (2) |
| Local Pruritus/Eczema |
0 |
4 (2) |
| Moderate |
32 (8) |
2 (1) |
| Headache |
24 (7) |
2 (1) |
| Fever |
4 (3) |
0 |
| Vomiting |
4 (3) |
0 |
| Urticaria |
0 |
0 |
| Severe |
1 (1) |
0 |
| Dyspnea cyanosis meningism |
1 (1) |
0 |
| Total episodes |
36 (10) |
34 (6) |
| Total infusions |
270 |
1152 |
| Rate (episodes/infusion) |
0.13 |
0.02 |
The reports of adverse effects of each patient have individual variations, considering
the method of home self register.
*IVIgG: Intravenous Immunoglobuline G.
†SCIgG: Subcutaneous Immunoglobuline. |
